CA3115522A1 - Uses of modified rna encoding retinaldehyde dehydrogenase - Google Patents

Uses of modified rna encoding retinaldehyde dehydrogenase Download PDF

Info

Publication number
CA3115522A1
CA3115522A1 CA3115522A CA3115522A CA3115522A1 CA 3115522 A1 CA3115522 A1 CA 3115522A1 CA 3115522 A CA3115522 A CA 3115522A CA 3115522 A CA3115522 A CA 3115522A CA 3115522 A1 CA3115522 A1 CA 3115522A1
Authority
CA
Canada
Prior art keywords
virus
vaccine
protein
species
raldh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3115522A
Other languages
English (en)
French (fr)
Inventor
Ulrich H. Von Andrian
Bruno RAPOSO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CA3115522A1 publication Critical patent/CA3115522A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01036—Retinal dehydrogenase (1.2.1.36)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
CA3115522A 2018-10-10 2019-10-10 Uses of modified rna encoding retinaldehyde dehydrogenase Pending CA3115522A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743943P 2018-10-10 2018-10-10
US62/743,943 2018-10-10
PCT/US2019/055543 WO2020077045A1 (en) 2018-10-10 2019-10-10 Uses of modified rna encoding retinaldehyde dehydrogenase

Publications (1)

Publication Number Publication Date
CA3115522A1 true CA3115522A1 (en) 2020-04-16

Family

ID=70164700

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3115522A Pending CA3115522A1 (en) 2018-10-10 2019-10-10 Uses of modified rna encoding retinaldehyde dehydrogenase

Country Status (6)

Country Link
US (2) US20210338709A1 (OSRAM)
EP (1) EP3863646A4 (OSRAM)
JP (1) JP2022512686A (OSRAM)
AU (1) AU2019356940A1 (OSRAM)
CA (1) CA3115522A1 (OSRAM)
WO (1) WO2020077045A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4284832A1 (en) * 2021-01-29 2023-12-06 (INSERM) Institut National de la Santé et de la Recherche Médicale Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119083A2 (en) * 2005-04-29 2006-11-09 Cbr Institute For Biomedical Research, Inc. Treating gastrointestinal diseases with modulation of retonic acid
AU2012304313A1 (en) * 2011-09-08 2014-03-06 University Of Florida Research Foundation, Inc. Materials and methods for modulating immune responses
US20160051669A1 (en) * 2014-08-21 2016-02-25 Georgia Regents University Research Institute, Inc. Compositions and methods for selectively modulating tregs
US10238741B2 (en) * 2014-10-10 2019-03-26 The Trustees Of Columbia University In The City Of New York Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
ES3011733T3 (en) * 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
JP6534146B2 (ja) * 2015-06-10 2019-06-26 国立大学法人 東京大学 ワクチン用アジュバント、ワクチン、及び免疫誘導方法
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein

Also Published As

Publication number Publication date
WO2020077045A1 (en) 2020-04-16
US20210338709A1 (en) 2021-11-04
AU2019356940A1 (en) 2021-05-13
US20250339458A1 (en) 2025-11-06
JP2022512686A (ja) 2022-02-07
EP3863646A4 (en) 2022-09-28
EP3863646A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
JP7675052B2 (ja) Ｒｎａの投与のための配合物
CN108430456B (zh) 癌症疫苗
JP7668111B2 (ja) Ｒｎａの投与のための配合物
CN116670267A (zh) 流感病毒的四价mRNA疫苗
US20250339458A1 (en) Uses of modified rna encoding retinaldehyde dehydrogenase
CN1194002C (zh) 短链化多核苷酸及其制备方法
US20260062716A1 (en) Lipid nanoparticle (lnp) composition or formulation for nucleic acid therapeutics
JP2025503994A (ja) コロナウイルスワクチン
WO2023069551A1 (en) Multi-epitope mrna sars-cov-2 vaccine for boosting immunity through the activation of cd4 and cd8 t cells as well as b lymphocytes
KR20200134255A (ko) 조성물
CN117580587A (zh) 基于源自SARS-CoV-2奥密克戎毒株的序列的冠状病毒核酸疫苗
JP2024539089A (ja) 修飾複製可能ｒｎａの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用
JP2024517642A (ja) ウイルスワクチン
CN111587114A (zh) 用于调节人免疫应答的咪唑并嘧啶的用途
CN117460827A (zh) 狂犬病核酸疫苗
JP2024522179A (ja) 免疫エフェクタ細胞の活性化および標的化のための薬剤および方法
JP2024514364A (ja) 緩衝物質を含むｒｎａ組成物ならびにその製造、保存および使用のための方法
US20250041278A1 (en) Tlr8 agonist for modulating immune response
US20250000971A1 (en) Tlr4 agonist for modulating immune response
Gómez-Aguado 3.2 Nucleic acid delivery systems
Genito Generation of Immune Tolerance with Combined Pharmacological Agents
EP4408886A1 (en) Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
WO2026082899A2 (en) Rna for preventing or treating tuberculosis
HK40102659A (zh) 病毒疫苗
CN117615752A (zh) 包含缓冲物质的rna组合物及其制备、储存和使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220803

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106